ATE515266T1 - 2-(amino-3,4-dioxo-1-cyclobuten-1- yl)aminoalkylsäure-derivate für die schmerzbehandlung - Google Patents

2-(amino-3,4-dioxo-1-cyclobuten-1- yl)aminoalkylsäure-derivate für die schmerzbehandlung

Info

Publication number
ATE515266T1
ATE515266T1 AT02789180T AT02789180T ATE515266T1 AT E515266 T1 ATE515266 T1 AT E515266T1 AT 02789180 T AT02789180 T AT 02789180T AT 02789180 T AT02789180 T AT 02789180T AT E515266 T1 ATE515266 T1 AT E515266T1
Authority
AT
Austria
Prior art keywords
aminoalkylic
cyclobuten
dioxo
amino
acid derivatives
Prior art date
Application number
AT02789180T
Other languages
English (en)
Inventor
Michael Brandt
Margaret Zaleska
John Moyer
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Application granted granted Critical
Publication of ATE515266T1 publication Critical patent/ATE515266T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02789180T 2001-10-10 2002-10-09 2-(amino-3,4-dioxo-1-cyclobuten-1- yl)aminoalkylsäure-derivate für die schmerzbehandlung ATE515266T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32824501P 2001-10-10 2001-10-10
PCT/US2002/032252 WO2003031416A2 (en) 2001-10-10 2002-10-09 [[2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain

Publications (1)

Publication Number Publication Date
ATE515266T1 true ATE515266T1 (de) 2011-07-15

Family

ID=23280159

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02789180T ATE515266T1 (de) 2001-10-10 2002-10-09 2-(amino-3,4-dioxo-1-cyclobuten-1- yl)aminoalkylsäure-derivate für die schmerzbehandlung

Country Status (26)

Country Link
US (2) US7098200B2 (de)
EP (1) EP1434588B1 (de)
JP (1) JP4350512B2 (de)
KR (1) KR100922703B1 (de)
CN (1) CN100448449C (de)
AR (1) AR036764A1 (de)
AT (1) ATE515266T1 (de)
AU (1) AU2009201746A1 (de)
BR (1) BR0213237A (de)
CA (1) CA2461348C (de)
CY (1) CY1111909T1 (de)
DK (1) DK1434588T3 (de)
EA (1) EA009993B1 (de)
ES (1) ES2367356T3 (de)
HU (1) HUP0401773A3 (de)
IL (2) IL161275A0 (de)
MX (1) MXPA04003354A (de)
NO (1) NO20041378L (de)
NZ (1) NZ532159A (de)
PL (1) PL368863A1 (de)
PT (1) PT1434588E (de)
SI (1) SI1434588T1 (de)
TW (1) TWI321472B (de)
UA (1) UA78529C2 (de)
WO (1) WO2003031416A2 (de)
ZA (1) ZA200403406B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE465726T1 (de) 2002-11-22 2010-05-15 Gruenenthal Gmbh Verwendung von (1r, 2r)-3-(3-dimenthylamino-1- ethyl-2-methyl-propyl)-phenol zur behandlung von entzündungsschmerz
PT1611144E (pt) * 2003-04-09 2010-11-12 Wyeth Llc Derivados do ácido 2-(8,9-dioxo-2,6-diazabiciclo(5.2.0)- non-1(7)-eno-2-il)-alquil-fosfónico e sua utilização como antagonistas do receptor n-metil-d-aspartato (nmda)
BRPI0409088A (pt) * 2003-04-09 2006-04-11 Wyeth Corp composições farmacêuticas para administração intranasal de ácido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0]non-1(7)-en-2-il)alquil]-fosfÈnico e derivados e métodos de uso dos mesmos
US20050142192A1 (en) * 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
GT200400213A (es) * 2003-10-22 2007-09-05 Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo
US7268123B2 (en) * 2004-10-08 2007-09-11 Wyeth Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of making them
MX2010002191A (es) * 2007-08-27 2010-03-17 Wyeth Llc Composiciones y metodos que emplean antagonistas nmda para lograr un efecto anestesico limitado.
EP2395999B1 (de) 2009-02-13 2017-09-13 Allergan, Inc. Pharmazeutische zusammensetzungen mit (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
CN102356087A (zh) 2009-03-19 2012-02-15 惠氏有限责任公司 [2-(8,9-二氧代-2,6-二氮杂双环[5.2.0]壬-1(7)-烯-2-基)乙基]膦酸及其前体的制备方法
WO2013078151A1 (en) 2011-11-21 2013-05-30 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
US10292989B2 (en) 2014-03-28 2019-05-21 University Of Virginia Patent Foundation General anesthetics that are not neurotoxic

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168103A (en) * 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5124319A (en) * 1991-10-11 1992-06-23 American Home Products Corporation Benzimidazole phosphono-amino acids
DK124393D0 (da) * 1993-11-03 1993-11-03 Lundbeck & Co As H Compounds
AT400440B (de) * 1993-12-06 1995-12-27 Vianova Kunstharz Ag Verfahren zur herstellung von wasserverdünnbaren lackbindemitteln und deren verwendung
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
UA52698C2 (uk) * 1996-10-04 2003-01-15 Х. Луннбек А/С Похідні (3-алкоксіізоксазол-4-іл)заміщеної 2-амінокарбонової кислоти та їх сірковмісні аналоги, фармацевтична композиція на їх основі
US5990307A (en) * 1997-08-01 1999-11-23 American Home Products Corporation Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid
KR100606580B1 (ko) 1997-08-01 2006-08-01 와이어쓰 [2-((8,9)-디옥소-2,6-디아자비사이클로[5.2.0]-논-1(7)-엔-2-일)에틸]포스폰산의 제조방법
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
US20030158254A1 (en) 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
US20040082543A1 (en) 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain

Also Published As

Publication number Publication date
CA2461348A1 (en) 2003-04-17
CN100448449C (zh) 2009-01-07
HUP0401773A3 (en) 2005-06-28
CY1111909T1 (el) 2015-11-04
EP1434588A2 (de) 2004-07-07
CN1568189A (zh) 2005-01-19
HK1064609A1 (en) 2005-02-04
MXPA04003354A (es) 2004-09-28
CA2461348C (en) 2011-02-15
JP4350512B2 (ja) 2009-10-21
TWI321472B (en) 2010-03-11
WO2003031416A2 (en) 2003-04-17
PL368863A1 (en) 2005-04-04
NO20041378L (no) 2004-05-28
EP1434588B1 (de) 2011-07-06
US7098200B2 (en) 2006-08-29
NZ532159A (en) 2006-02-24
AU2009201746A1 (en) 2009-05-28
IL161275A (en) 2009-09-01
US7759346B2 (en) 2010-07-20
KR20050034604A (ko) 2005-04-14
ES2367356T3 (es) 2011-11-02
BR0213237A (pt) 2004-09-28
DK1434588T3 (da) 2011-08-15
WO2003031416A3 (en) 2003-08-14
HUP0401773A2 (hu) 2005-01-28
EA009993B1 (ru) 2008-06-30
JP2005508950A (ja) 2005-04-07
US20060205696A1 (en) 2006-09-14
KR100922703B1 (ko) 2009-10-22
PT1434588E (pt) 2011-09-05
SI1434588T1 (sl) 2011-10-28
US20030114444A1 (en) 2003-06-19
UA78529C2 (en) 2007-04-10
ZA200403406B (en) 2007-04-25
IL161275A0 (en) 2004-09-27
EA200400523A1 (ru) 2004-08-26
AR036764A1 (es) 2004-09-29

Similar Documents

Publication Publication Date Title
NO20035156D0 (no) Fremgangsmåter for brönnbehandling
DE60316538D1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
ATE441417T1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
LTPA2014019I1 (lt) Fenetanolamino dariniai, skirti kvėpavimo ligoms gydyti
ATE288431T1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
BR0313373B1 (pt) processo para fabricação contìnua de artigos descartáveis de vestir.
DE502004002801D1 (de) Bohrlochbehandlungsmittel, enthaltend ethercarbonsäuren
ATE502642T1 (de) Kombinationen für die behandlung von immun- entzündlichen erkrankungen
FI20010705L (fi) Menetelmä peretikkahapon valmistamiseksi
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
ATE478653T1 (de) Behandlungsmittel für die nasse haut
FI20012098L (fi) Menetelmä perkarboksyylihapon valmistamiseksi
NL1021504A1 (nl) Waterstofbehandelingsproces.
DK1434588T3 (da) 2-(amino-3,4-dioxo-1cyclobuten-1-yl)aminoalkylsyrederivater til behandling af smerte
DE60220220D1 (de) Blutbehandlungssystem
FI20010706L (fi) Menetelmä perkarboksyylihapon valmistamiseksi
ATE374011T1 (de) Hautbehandlungsmittel
EP1565448A4 (de) VERFAHREN ZUR HERSTELLUNG VON10H-DIBENZOçB, F] ç1,4]THIAZEPIN-11-ON
DE60133596D1 (de) S-Methyl-Dihydro-Ziprasidone für die Behandlung von Schizophrenie
ATE253556T1 (de) Aminoacylaroylpyrrole für die behandlung des neuropathischen schmerzes
ITTO20010222A0 (it) Macchina per il trattamento di olive.
EP1295864A4 (de) Verfahren zur herstellung von 1,5-diaminonaphthalinen
ITTO20020997A1 (it) Procedimento autoalllineato per la fabbricazione di
EP1177789A3 (de) Verwendung von Phytansäure zur Diabetesbehandlung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1434588

Country of ref document: EP